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Mechanism of actionAbstract Traditionally, two divergent approaches are used to explain the mechanism of action of
psychotropic drugs. The dominant ‘‘Disease-centred” view emphasises the biochemical imbalance
caused by ‘illnesses’. In contrast the ‘‘Drug-centred” view emphasises the psychoactive properties
of these drugs and their ability to induce an ‘altered-state’ of mind. In this article we propose a
new paradigm for classifying the therapeutic uses of psychotropic drugs based on the relation
between their psychoactive effects and symptoms of indicated mental illness; as well as their clinical
responses e.g. emerging tolerance, paradoxical initial worsening and being recommended for long/
short term use. Based on this premise, therapeutic uses of psychotropic drugs can be placed on a
continuum between two distinguishable modes. We deﬁne these modes as ‘‘Psycho-antagonistic”
and ‘‘Psycho-agonistic”. 105 therapeutic uses of 85 psychotropic drugs are placed on this contin-
uum; 74% on the Psycho-agnostic spectrum and 25% on the Psycho-antagonistic side. Hypnotic
agents used for insomnia are clear examples of Psycho-antagonistic mode of use. Citalopram for
treatment of Panic disorder is a clear example of using a drug in Psycho-agonistic mode. Only
the therapeutic use of Lithium for bipolar affective disorder could not be allocated to any mode
and considered as borderline. The paradigm highlights the possibility of initial worsening in major-
ity of therapeutic uses of psychotropic drugs and importance of using lower doses. Further studies
and clinical trials are needed to explore the full extent of the clinical implications of this paradigm in
psychiatry and perhaps in other branches of medicine.
 2016 Tehran University of Medical Sciences. Published by Elsevier Ltd. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1 The continuum of therapeutic uses.
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Psychotropic drugs are used successfully to treat mentally
unwell patients. Alteration in brain neuro-chemistry has been
the best evidenced and most accepted explanation of the effects
of such drugs since the 1950–60 s [1]. Indeed most of the recent
advances in our pharmacological toolkit are due to scientiﬁc
advances and clinical trials based on this ‘Disease-centred’
model. This model has replaced an older, more clinically ori-
ented model of how psychotropic drugs may work. This latter
approach is based on the concept of the psychoactive proper-
ties of psychotropic medication and the possibility of inducing
an altered mental state to explain the mechanism of action of
same [2]. For example, Deniker in 1960 suggested that neu-
roleptic drugs work by inducing a neurological syndrome con-
sisting of physical restriction and mental symptoms such as
cognitive slowing, apathy, and emotional ﬂattening, which
resembled Parkinson’s disease [3].
This point of view has recently led to the development of a
‘Drug-centred’ model by Dr. Joanna Moncrieff [4] to explain
the mechanism of action of psychotropic drugs. In this
approach the effect of psychotropic drugs are considered to
be similar to the effects of psychoactive substances that:
‘‘induce complex, varied, often unpredictable physical and
mental states that patients typically experience as global,
rather than distinct therapeutic effects and side effects” and
that their ‘‘therapeutic effects are the consequence of being
in an altered mental state” [4]. Whilst the model is clearly at
odds with current scientiﬁc thinking, there may be some beneﬁt
in exploring how psychological alterations produced by
psychotropic drugs interact with the symptoms experienced
by patients with clearly deﬁned mental illness.
In addition, Moncrieff’s model suggests that any such
approach needs to consider the psychological changes due to
psychotropic drugs on healthy subjects – otherwise the effect
of the drug may be altered or masked by the symptoms of
the illness. For example the sedative properties of a drug might
be completely different when prescribed to an aroused in con-
trast to a drowsy patient. In reality however, it is rare to ﬁnd
such studies on healthy subjects in the published medical liter-
ature [4].
Within the spirit of an exploratory approach to the interac-
tion between the psychoactive properties of a psychotropic
drug and the symptoms of mental illness that it is licensed to
treat we propose an alternative option. This is to use the pub-
lished summaries of the toxicity and side effect proﬁles of each
psychotropic drug as a proxy measure of their psychoactive
effect in a healthy subject. This information also presents the
unintended but still psychoactive properties of psychotropicTable 1 Modes of therapeutic uses.
Mode Deﬁnition of therapeutic use
Psycho-antagonistic 1. The drug’s psychoactive effec
2. It is recommended for short t
3. Tolerance is likely to develop
Psycho-agonistic 1. The drug’s psychoactive effec
2. It is recommended for longer
without the development of to
3. There is a possibility of an indrugs. In clinical practice the interface between the therapeutic
properties and side effects of a drug becomes blurred on some
situations. Using the reported side effect of Mirtazapine of ‘in-
creasing appetite’ as a desirable property in treating an anorexic
patient with depression is a good example of how reported side
effects can have therapeutic uses [5]. Therefore, in this article we
shall use the terms ‘Side-effect’ and ‘Psychoactive properties/
effects’ synonymously and interchangeably.
Hypothesis
Based on this premise, we propose that therapeutic uses of psy-
chotropic drugs can be placed on a continuum between two
distinguishable modes. Their locus along the continuum is
based on the relationship between their psychoactive effects
and the symptoms of the illness for which they are prescribed
in addition to their therapeutic responses. We deﬁne these
modes as ‘‘Psycho-antagonistic” and ‘‘Psycho-agonistic” and
their deﬁning characteristics are outlined below (Table 1).
We propose that all psychotropic drugs could be placed
along this continuum as illustrated (Fig. 1) by using the num-
ber of the criteria they meet. It is important to highlight here
that the terms Psycho-antagonistic and Psycho-agonistic are
descriptive only and do not imply any disease-targeted mecha-
nism or receptor oriented theory.
Evaluation of hypothesis
The ﬁrst and second authors (FS & MG) conducted a review
of the medical literature on the reported side effect proﬁle
and clinical responses of psychotropic medication in relation
to the symptoms of those mental illnesses they are prescribed
to treat (clinical indication). They independently reviewed each
drug in the British National Formulary’s (BNF) classes 4.1–4.4
and 4.11 [6] along with their speciﬁc clinical indications, from
August 2009 to Nov 2015. Any discrepancy was discussed in
order to arrive at a consensus. In the BNF the clinical indica-
tions are listed as an illness/mental disorder (e.g. Schizophre-
nia) or a symptom (e.g. insomnia). In the case of mental
illness/disorder, the symptom proﬁle was taken from the deﬁ-
nition of the illness/disorder as speciﬁed in the International
Classiﬁcation of Diseases, 10th edition (ICD-10) [7]. In thet is opposite to the symptoms of its indicated mental illness/disorder
erm use
with use over a few weeks
t mimics the symptoms of its indicated mental illness/disorder
term use. ‘Symptom reduction’ occurs gradually over time
lerance
itial worsening of some symptoms
S26 F. Shaddel et al.next step the side effect proﬁle of each drug as described in the
BNF and clinical responses were noted. For each drug, the
side-effect proﬁle was cross-matched to the indication proﬁle
listed for that drug.
For example drowsiness is one of the side effects (psychoac-
tive effect) of Zopiclone used as a hypnotic, which is opposite
to insomnia [6]. In addition, Zopiclone is recommended for
short-term treatment of insomnia as one develops tolerance
in few weeks after initial therapeutic response. Therefore the
use of Zopiclone for treatment of insomnia is strongly in
Psycho-antagonistic mode. On the other hand, Citalopram is
licensed for the treatment of Panic disorder. The BNF has
identiﬁed ‘‘palpitation, tachycardia, impaired concentration,
paraesthesia, dry mouth, nervousness, anxiety, insomnia, tre-
mor, dizziness...” as potential side effects (psychoactive effects)
of Citalopram with less sedative effect comparing to other
anti-anxiety drugs. These effects resemble the symptoms of a
panic attack. In addition, the possibility of paradoxical wors-
ening of anxiety during the initial treatment of Panic disorder
and its use for long term treatment are well established [6].
Therefore, the therapeutic use of Citalopram for treatment
of Panic disorder is strongly in Psycho-agonistic mode (covers
all three criteria). But when the Citalopram is used for the
treatment of depression, however, its therapeutic use is still
in Psycho-agonistic mode but less strongly. BNF has reported
both ‘‘suicidality, impaired concentration, sexual dysfunction
and insomnia,..” (which resembles the symptoms of a depres-
sive episode) and hypomania/mania which is opposite of
depression. The possibility of paradoxical worsening of suici-
dality and anxiety in the initial treatment and suitability of
using the medication for long-term treatment are well known
[6]. Therefore it covers only two criteria from the Psycho-
agonistic mode. In situations where the information on the
psychoactive effects of a drug and their clinical responses listed
in the BNF were inconclusive, we used the Maudsley prescrip-
tion guides [8] and other medical literature to guide decision
making [9–11].
Empirical data
85 psychotropic drugs were cross-matched to their BNF listed
indications resulting in the identiﬁcation of 105 ‘therapeutic
uses’. It was possible to place all these therapeutic uses on aStrongly 
Psycho-antagonisc 
Figure 2 Mode of therapeutic uscontinuum between two Psycho-antagonistic or Psycho-
agonistic modes as deﬁned above (Fig. 2, Table 2).
Most therapeutic uses (97 out of 105 or 91%) can be allo-
cated with reasonable conﬁdence (meeting two or more crite-
ria) into either Psycho-agonistic or Psycho-antagonistic
mode. Only the therapeutic use of Lithium for bipolar affective
disorder could not be allocated to any mode and considered as
borderline. (Table 2).
The other ﬁnding to emerge was that some individual drugs
can be used in both Psycho-antagonistic and Psycho-agonistic
modes – depending on their side-effect proﬁle and different
treatment indications. It was noted that the likely therapeutic
responses shifted to that which was characteristic of the thera-
peutic mode of use. For example Olanzapine is used for the
long term treatment of schizophrenia which is aligned with a
Psycho-agonistic use of drug (Table 2). Gradual ‘symptom
reduction’ without developing tolerance and possibility of ini-
tial worsening of some symptoms (Akathisia) are aligned with
therapeutic responses to Psycho-agonistic mode as well. How-
ever, when the sedative effect of Olanzapine is used to treat
severe agitation in a patient with acute psychosis (rapid tran-
quilisation), it is used in a Psycho-antagonistic mode. Here
the therapeutic responses are quick and emergence of tolerance
(with requirement for increased drug doses) with longer term
use [6,8] have been reported (Table 2).
Discussion
The current classiﬁcation of the way psychotropic drugs are
used within the BNF [6] is by action of a drug on an ‘‘illness”
i.e. antipsychotics, antidepressants etc. However, due to devel-
opments in our understanding of the drug’s structure and/or
receptor mechanisms there are subcategories within classes
(e.g. tricyclics and SSRIs within the antidepressant class). Fur-
thermore, it has become clear that drugs licensed for the treat-
ment of speciﬁc illnesses are helpful in treating other illnesses
(e.g. Venlafaxine for depression and anxiety disorders; Queti-
apine for psychosis and bipolar depression) though with differ-
ent recommended doses.
This paper is the ﬁrst (as far as we are aware) to draw atten-
tion to the relationship between the ‘Psychoactive properties of
a drug’ and the ‘Symptoms of illness’ for which it is an indi-
cated treatment and to use that relationship to conceptualiseStrongly 
Psycho-agonisc 
es of psychotropic medication.
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S28 F. Shaddel et al.the ‘‘therapeutic uses” of psychotropic drugs in a different
way. Accommodating this conceptual shift is perhaps the main
challenge as it requires us as psychiatrists to reﬂect and think
more critically on our prescribing decisions and patients’
responses to them, pending more research on the pathophysi-
ology of psychiatric disorders. This requires, within an
exploratory (or extended thought experiment) context, being
mindful of alternative models and their potential signiﬁcance
both explicit and hidden, to prescribing decisions.
The more explicit model is disease centred. The focus is on
the ‘‘target” response to the drugs only and that ‘‘non-target”
effects are understood as secondary by-products and unwanted
generally. This concept is underlined by the language used to
describe these other effects i.e. as ‘‘side effects”. An alternative
concept considers all the drug effects as primary. These effects
may be useful (therapeutic) or troublesome (side-effects)
depending on the symptoms of illness they are used to treat.
In this paper the focus is on considering the ill and healthy per-
son’s response to psychotropic drugs. Ironically, clinical prac-
tice can be seen as pragmatic in that prescribing decisions tend
to use elements of both approaches – selecting agents with a
side-effect proﬁle that treat speciﬁc symptoms as well as target-
ing the underlying pathophysiology of the illness. For example
Mirtazapine for treatment of a patient with depression who
has marked insomnia. The prescriber’s rationale for choosing
an ‘‘Anti-depressant” is likely to refer to the ‘‘Disease-
centred” model or known receptor proﬁle of the prescribed
agent. However, the decision about which anti-depressant is
likely here to be on the secondary by-product of sedation/
drowsiness of the drug (side effect). This is entirely appropriate
and effective. However, are there any clinical advantages to
making the hidden aspects of these decisions more explicit?
More speciﬁcally, does a more explicit focus on a therapeutic
use and response paradigm confer any potential clinical
beneﬁts?
To answer these questions, it is important to acknowledge
the limitations of our study in advance. In terms of methodol-
ogy, the main limitation was using the BNF side-effect proﬁle
of drugs as a proxy measure of their effects in healthy subjects.
Given the constraints of conducting studies in healthy subjects,
this approach may be acceptable as part of an exploratory
approach. However, this means that currently the paradigm
may not be able to explain all the reported paradoxical beha-
viours of psychotropic drugs for the same reason. The psy-
chogenic properties of drugs are largely predetermined and
therefore predictable. However we can only observe their inter-
action with the illness through the window of a human bodyFigure 3 Psycho-antagwhich may respond uniquely either to the illness and/or the
drug itself, as noted by the ‘‘endophenotype” theory [12].
Proper ‘‘ﬁt for purpose” studies with large numbers of healthy
subjects are needed therefore to address these issues (although
they cannot be totally eliminated). And last but not least, we
have refrained from including the off-license and add-on use
of psychotropic drugs to avoid further complexity of interpre-
tation. Whilst acknowledging these limitations, we have shown
that:
– Firstly it is possible to identify therapeutic uses of psy-
chotropic agents based on the BNF descriptors and to allo-
cate almost all of them (except lithium for bipolar affective
disorder) with a reasonable conﬁdence (two or more criteria
met) along a continuum between Psycho-antagonistic and
Psycho-agonistic modes. The categorisation is clearly differ-
ent to that of the BNF.
– Secondly each group predicts likely characteristic therapeu-
tic responses. The Psycho-antagonistic mode of use was
associated with likely earlier symptom improvement but
with gradual loss of effect after rather a short period. In
contrast the Psycho-agonistic mode of use was associated
with a delay to symptom reduction (and with possible initial
worsening of symptoms) but with sustained clinical
improvement. We have conceptualised the clinical
responses to drugs when they are used in Psycho-agonistic
or Psycho-antagonistic mode in Figs. 3 and 4.
The clinical utility of this approach lies in these likely ther-
apeutic responses. For example consider these two common
clinical scenarios after initiating Risperidone 0.5 mg once a
day for challenging behaviour of a patient with severe intellec-
tual disability. We have chosen a person with severe intellec-
tual disability to minimise the placebo effect.
Scenario one: The carers reported a signiﬁcant improve-
ment in the patient’s sleep, mood and challenging behaviour
after the ﬁrst dose of Risperidone. These changes gradually
reverted to the initial clinical presentation after 2–3 weeks.
Scenario two: The carers reported a gradual partial
improvement in the patient’s sleep pattern as well as in the
intensity and frequency of challenging behaviours during the
ﬁrst 4–5 weeks after drug initiation. These changes have been
maintained.
What should one decide about the Risperidone in each sce-
nario? Current psychopathology and literature remain largely
silent about distinguishing such subtle differences in clinical
responses and leave the decision to the clinical judgement ofonistic use of drugs.
Figure 4 Psycho-agonistic use of drugs.
How psychotropic drugs are used; an explanatory paradigm S29the practitioner. Therefore, there might be an inconsistency in
recommendations made by practitioners here. But let’s see if
our paradigm can be used as a complementary to other models
and guidelines to ﬁll in such gaps.
Given the clinical responses, we can clearly recognise a
Psycho-antagonistic mode of therapeutic use of Risperidone
in the ﬁrst scenario and a psych-agonistic mode in the second.
In the former, most probably, the sedative effect of Risperi-
done has ameliorated the patient’s symptoms quickly but tol-
erance to this effect has gradually developed. Therefore,
increasing the dose of Risperidone is unlikely to result in a sus-
tained clinical improvement. In contrast, in the latter scenario,
the clinical response is aligned with a psych-agonistic mode of
the drugs’ therapeutic use and therefore, continuing or increas-
ing the dose is likely to result in sustained clinical improve-
ment. Of course, the validity of such clinical predictions
needs to be veriﬁed through robust clinical studies and trials.
In addition, grouping psychotropic drugs based on their
therapeutic uses would make it easier for clinicians to predict
and explain to patients their possible early response to the drug
prescribed, the time to onset of the desired clinical beneﬁts and
the consequences of sustained use. The paradigm would raise
the awareness of clinicians and patients of the possibility of ini-
tial worsening of symptoms and how to manage them – i.e. by
reducing the dose. The management of initial worsening of
Panic disorder (when treated with Citalopram) is a good exam-
ple [6]. However in our opinion, the extent of current aware-
ness about the likelihood and signiﬁcance of initial
‘‘paradoxical” symptom development is far less than what
our paradigm indicates to be appropriate. Our study shows
that ‘initial worsening’ is a potential feature of about 74% of
therapeutic uses with a preponderance of enduring illness
(depression and schizophrenia) indications. When translated
to clinical practice, this awareness should inﬂuence prescribing
decisions towards the ‘lower doses’ so as to minimise these
risks and to assure a less distressing and more successful
patient outcome. This is similar, but conceptually different
to, recommendations that ‘‘less is more” derived from several
other ‘‘disease centred” studies recommending smaller doses
of psychotropic medication (e.g. Haloperidol and Risperidone)
for better clinical results [13–16].
Whilst these advantages (and potential beneﬁts) seem self-
evident, clearly further clinical studies are needed to conﬁrm
the validity of these ﬁndings and explore the full extent of their
clinical implications in psychiatry and perhaps in otherbranches of medicine. In addition, a new line of research would
be on deﬁning the psychoactive effect of psychotropic drugs on
healthy subjects as identiﬁed by Dr. Moncriff [4] to avoid any
interaction with the patient’s symptoms.Overview box:
What do we already know about the subject?
The mechanism of action of psychotropic drugs are
explained by two approaches. The dominant ‘‘Disease-
centred” view emphasises the biochemical imbalance
caused by ‘illnesses’. In contrast the ‘‘Drug-centred” view
emphasises the psychoactive properties of these drugs and
their ability to induce an ‘altered-state’ of mind.
What does your proposed theory add to the current
knowledge available, and what benefits does it have?
The paradigm highlights the possibility of initial wors-
ening in majority of therapeutic uses of psychotropic
drugs and importance of using lower doses in psychiatry.
The paradigm complements current guidelines for making
decision in different clinical scenarios.
Among numerous available studies, what special further
study is proposed for testing the idea?
Whilst these advantages (and potential beneﬁts) seem
self-evident, clearly further properly designed (ﬁt for pur-
pose) clinical studies are needed to conﬁrm the validity of
these ﬁndings and explore the full extent of their clinical
implications in psychiatry and perhaps in other branches
of medicine.Conflict of interest
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